Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 164 participants.
Also called NCT05084118
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 164 participants
- Sponsor
- Registry
-
NCT05084118
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Austria
- Registry status
- Unknown status
Technical summary
Registry record NCT05084118. Randomized; quadruple masking; primary purpose prevention. Start 2021-10-21 (actual); primary completion 2023-11-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Landiolol for Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery
- Acronym
- LANDI-POAF
- Condition
- Atrial Fibrillation
- Condition
- Postoperative Complications
- Intervention (Drug)
- Landiolol HCl
- Intervention (Drug)
- Placebo
- Lead sponsor
- Medical University of Vienna
Record details
- Record id
cardio:ct-nct05084118- Content hash
b87eb8cc6ed3097cd7915a9daea7d18f7c216510a9698bcf35004bcb85be21e2